Litcius/Paper detail

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study

Warner K. Huh, William E. Brady, Paula M. Fracasso, Don S. Dizon, Matthew A. Powell, Bradley J. Monk, Charles A. Leath, Lisa M. Landrum, Edward J. Tanner, Erin K. Crane, Stefanie Ueda, Michael McHale, Carol Aghajanian

2020Gynecologic Oncology78 citationsDOIOpen Access PDF

Topics & Concepts

MedicineGynecologic oncologyInternal medicineCervical cancerProgression-free survivalOncologyBevacizumabPopulationAdverse effectPhases of clinical researchStage (stratigraphy)ChemotherapyCancerBiologyPaleontologyEnvironmental healthImmunotherapy and Immune ResponsesEndometrial and Cervical Cancer TreatmentsCervical Cancer and HPV Research
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study | Litcius